Unintended benefits by Roche and Burroughs Wellcome

2206. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Government had ordered an enquiry in respect of sales of formulations based on Trimenthoprim and Sulphamethoxazole in regard to unintended profits made by Roche and Burroughs Wellcome on the basis of instances which came to Government' notice about purchase of these drugs at much cheaper prices;

(b) so, when such instances or complaints came to Government's notice and whether any investigation was done;

(c) if so, when and who investigated these issues;

(d) when was the report finalised and what was the final decision taken;

(e) whether it is also a fact that these companies made crores of rupees as unintended benefits;

(f) if so, whether any amount has been recovered on this account; and

(g) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) No such enquiry has been ordered.

(b) to (g) Government is not aware whether Roche Products Limited or Burroughs Wellcome have procured any Trimethoprim/Sulphamethoxazole at prices lower than the Government fixed prices.

Manufacture of prednisolone

2207. SHRI RAJNI RANAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what is the stage from which Wyeth Laboratories have been permitted to manufacture Prednisolone;

(b) whether it is a fact that Wyeth Laboratories have been imported Hydrocortisone which is an intermediate for the production of prednisolone;

(c) if so, what is the quantity imported during the last three years, yearwise along with everage CIF price/Kg. along with source of import;

(d) whether any other company is licensed to produce this drug; and

(e) if so, what is the name of the company, capacity and stage of manufacture permitted along with the production during the last three years, year-wise?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) As reported by the Company, M/s. Wyeth Labs are producing Prednisolone from basic state.

(c) Does not arise.

(d) Yes, Sir.

(e) M/s. Tamil Nadu Dadha are licensed to produce 500 Kgs. per annum of Prednisolone. The Company is permitted to base the production on imported intermediates for a maximum period of two years. Thereafter, it is required to start the production from the basis stage. The Company has not yet reported commencement of production of Prednisolone.

इलाहाबाद में टेलीफोन

2208. **श्री सत्य प्रकाश मालवीय:** क्या संचार मंत्री यह बताने की कृपा करेंगे कि :

(क) 31 अक्तूबर, 1985 को उत्तर प्रदेश के इलाहाबाद जिले में टेलीफोन कनेक्शनों की कुल संख्या कितनी थी ;

(ख) 31 अक्तूबर, 1985 को इलाहाबाद में नये टेलीफोन कनेक्शन पाने के लिए लम्बित आवेदन पत्रों की कुल संख्या कितनी थी; और

(ग) इन आवेदकों को कब तक नये टेलीफोन कनेक्शनों दे दिये जाने की संभावना है ?

संचार मंत्रालय के राज्य मंत्री (श्री राम निवास मिर्धा : (क) 31-10-85 को इलाहाबाद में, 8,513 टेलीफोन कनेक्शन कार्य कर रहे थे।

(ख) 31-10-85 को इलाहाबाद में नए टेलीफोन कनेक्शनों के लिए 1621 नाम प्रतीक्षा-सूची में थे।

(ग) सातवीं योजना के दौरान वर्तमान प्रतीक्षा-सूची को उत्तरोत्तर निपटाए जाने की संभावना है।

Curtailment of production of essential drugs by M|s Glaxo Laboratories

2209. SHRI PRAVIN KUMAR PRAJAPATI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that according to the balance sheets of M|s. Glaxo Laboratories for period ending 30th June, 1984 and 1985 they indicated a continuous process of curtailment of production of essential medicines such as Vaccines and Antibiotics and excess production of ointments, tablets, liquid, and capsules,

(b) whether it is also a fact that the production of tablets, capsules, ointments and liquids in eight to ten times more than permitted capacity of each whereas production of vaccines and antibiotics indicates srortfall in the same ratio;

(c) if so, what are the reasons therefor;

(d) whether there is any provision under I (D&R) Act or Drug Policy to check unauthorised production and insist obligation of production of essential drugs; and

(e) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (c) The company tailors its production to the market demand; however, the company conforms to the ratio parameters eligible under the 1978 Drug Policy.

(d) and (e) Under the I(D&R) Act, manufacture without a valid industrial approval is an offence. A Company cannot be compelled to produce a particular product, whether essential or not.

Anti-TB Drug

2210. SHRI PRAVIN KUMAR PRAJAPATI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 965 given in the Rajya Sabha on the 25th November, 1985 and state:

(a) whether Ethambutol and Rifampicin are Anti-TB and Anti-Leprosy drugs;

(b) what is the mark up allowed on formulations based on these drugs and what is the mark up allowed on other anti-TB and Leprosy drugs alongwith name of each drug and mark up allowed in each case;

(c) whether it is a fact that since 1980 formulators have been making unintended benefits on these medicines if so what is the total amount worked out on these two drugs upto 30th November 1985;

(d) when did it come to the notice of Government;

(e) what are the names of companies to whom notices were issued along with date;

(f) what are the details of amount so far recovered on these medicines;

(g) whether it is also a fact that Ethambutol is available in open market at Rs. 550|- per Kg; and

(h) if so., what steps were taken to reduce the prices of Ethambutol formulations?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Rifampicin is an Anti-T.B. and Anti-Leprosy drug whereas Ethambutol is an Anti-T.B. drug only.

(b) Mark-up is allowed in accordance with the provisions of Drugs (Prices Control) Order, 1979 on Anti-T.B. and Anti-Leprosy drug.

(c) On account of the difference between the price of Rifampicin allowed in the formulations and the actual landed cost of import in spite of six reduction in prices between August 1981 and September 1984 certain excess amount had accrued to the